0:00
hello and welcome back to health
0:02
awareness today we'll be diving into the
0:04
exciting world of HIV research more
0:07
specifically a groundbreaking news study
0:09
that is focusing on a drug called gs8
0:12
588 this study could be a crucial step
0:14
in advancing the future of HIV
0:16
treatments and even a potential cure so
0:19
what is gs8 588 how does it work and
0:21
what does it work and what does it mean
0:23
for the future of HIV care stick around
0:26
and we'll break it all down first let's
0:30
set the stage with a little background
0:31
for decades the standard treatment for
0:33
HIV has been anti-retroviral therapy
0:36
also known as art this treatment
0:39
involves taking a daily regimen of drugs
0:41
that stop the virus from replicating in
0:43
the body allowing those with HIV to live
0:45
long and healthy lives art has been a
0:48
GameChanger for Millions but it's not a
0:51
cure people living with HIV must take
0:54
these medications for life to keep the
1:00
now let's talk about the company behind
1:02
gs8 588 Gilead Sciences Gilead has long
1:06
been a leading innovator in HIV
1:08
treatment and prevention helping
1:09
transform HIV from an inevitably fatal
1:12
condition to a chronic one that can be
1:13
well managed they also developed the
1:16
first pre-exposure prophylaxis prep
1:18
medication to help prevent HIV
1:21
transmission they believe their
1:23
continued research will one day lead to
1:25
a cure to help end the HIV epidemic for
1:28
everyone everywhere they optimize the
1:30
tools they have today and continue
1:32
bringing forward Innovative new
1:34
solutions to improve the care and
1:35
experiences of those living with or
1:39
HIV that is why gilled continues to
1:42
advance a varied pipeline of potential
1:43
future therapy options with the aim of
1:46
helping to address the diverse needs of
1:47
all people affected by HIV as we
1:50
continue to search for a cure HIV
1:54
treatment Gilead researchers have
1:56
developed some of the therapies that
1:58
have led the way in the Global Response
2:00
to HIV including the first single tablet
2:03
regimen but despite this progress
2:06
they've made over more than three
2:07
decades addressing HIV remains a serious
2:10
Public Health imperative around the
2:11
world stigma associated with treatment
2:14
persists in many communities and there
2:16
are new challenges to consider as
2:18
research advancements have enabled
2:20
people to live with HIV as a manageable
2:22
chronic condition HIV
2:26
prevention gilled introduced the First
2:28
Once daily oral medication for
2:30
pre-exposure prophylaxis prep to help
2:32
prevent HIV transmission between sexual
2:35
partners when taken as
2:37
prescribed advancing the science behind
2:39
prep and prevention strategies is a
2:41
fundamental part of our efforts to help
2:45
epidemic HIV treatment and prevention is
2:48
entering a new era where more
2:49
therapeutic options are emerging to meet
2:51
the diverse needs and preferences of
2:53
people living with HIV and those who
2:57
prep while the Advent of once daily
3:00
single tablet regimens helped
3:01
revolutionize Care by simplifying dosing
3:04
some people face challenges with
3:05
adherence due to limited treatment
3:07
options or a complex regimen in certain
3:10
areas around the globe taking daily
3:13
pills may also be a stigmatizing
3:15
burden long acting therapies are the
3:18
next wave of innovation with the
3:20
potential to further transform HIV Care
3:22
by addressing these barriers and
3:24
providing more flexible and accessible
3:27
options the path to cure
3:30
curing HIV Remains the ultimate
3:33
aspiration of Gilead's research and
3:36
efforts while HIV treatment has advanced
3:39
dramatically over the past three decades
3:41
an estimated 38 million people living
3:43
with HIV globally still face a lifetime
3:46
of anti-retroviral therapy art which
3:50
challenges since the start of the
3:52
epidemic they've been pursuing potential
3:54
Pathways to achieve a functional cure or
3:57
long-term viral remission in the ab Ence
4:00
of art for people living with HIV with
4:02
an aim to discover a therapy that can
4:04
achieve durable artfree HIV remission
4:07
without transmission or disease
4:10
progression but here's the challenge HIV
4:12
has a sneaky way of hiding in the body
4:14
forming something called a latent
4:16
Reservoir this is a pool of infected
4:18
cells where the virus remains dormant
4:20
undetectable by the immune system even
4:23
if someone's viral load is undetectable
4:25
while on Art HIV can still be lurking in
4:28
these reservoirs waiting to resurface if
4:32
stops this is why despite the success of
4:35
art researchers are constantly looking
4:37
for more long-term Solutions whether
4:39
that's a functional cure a vaccine or a
4:41
new form of therapy that can Target
4:45
reservoirs now this brings us to the gs8
4:48
588 study gs8 588 is a drug being tested
4:52
in a phase 1B clinical trial which means
4:54
the focus is on its safety and
4:56
tolerability in people who are already
4:58
virologically suppressed meaning their
4:59
viral loads are undetectable thanks to
5:02
Art this study specifically targets
5:05
people who are stable on Art which gives
5:07
researchers a controlled environment to
5:09
see how gs8 588 interacts with the
5:15
5888 what makes it different from other
5:18
treatments the drug is designed to
5:20
complement existing therapies possibly
5:22
targeting the virus in new
5:24
ways while art works by stopping the
5:26
virus from replicating gs8 588 could
5:29
offer additional mechanisms of action
5:31
such as directly targeting the virus's
5:33
ability to survive or replicate in these
5:37
reservoirs like other phase 1 trials
5:40
this study is all about Gathering data
5:42
on how the drug behaves in the human
5:44
body researchers are looking at the
5:46
pharmacogenetics that's the study of how
5:48
the body absorbs distributes metabolizes
5:51
and excretes the drug participants in
5:53
the study received gs8 588 via
5:56
intravenous infusion and the trial
5:58
measures the drug safety across
6:00
different dosing levels whether it's a
6:01
single dose or multiple doses over
6:04
time the ultimate goal is to see whether
6:07
gs8 588 could be part of a combination
6:10
therapy that might One Day lead to a
6:11
cure or at least a long-term remission
6:15
to clarify combination therapy means
6:17
that gs8 588 might work best alongside
6:20
other drugs and it's being tested in
6:22
virologically suppressed individuals
6:24
because they are already stable on their
6:26
treatment this offers a unique
6:28
opportunity to observe the drugs effects
6:31
without the complicating factor of
6:34
replication people who are virologically
6:37
supressed typically have undetectable
6:39
viral loads thanks to Art but the virus
6:42
isn't completely gone it's just
6:44
controlled these people are key
6:45
candidates for trials like gs8 588
6:48
because they offer a stable Baseline to
6:51
drugs and as we mentioned earlier one of
6:54
the big challenges in HIV research is
6:57
addressing the latent reservoirs and GSA
7:00
8,588 might help chip away at this
7:03
issue that said HIV cure research is
7:06
still in its early stages even though
7:09
this trial is a step forward it's
7:12
expectations this is just the beginning
7:15
and even if GS 8588 shows promise it
7:18
will need to go through multiple phases
7:19
of clinical trials before it can be
7:21
approved for widespread use trials like
7:24
this one often take years and involve
7:26
hundreds or even thousands of
7:28
participants before we get clear answers
7:29
on Effectiveness and long-term
7:32
safety but here's the exciting
7:35
part even though we are in the early
7:37
days every study like gs8 588 gives
7:40
researchers more information about how
7:42
the virus Works how it can be targeted
7:44
and what strategies might eventually
7:47
cure this knowledge also helps to fuel
7:50
further research and possibly leads to
7:52
the development of more targeted drugs
7:54
vaccines or treatments that could change
7:56
the landscape of HIV care
8:00
so what does the future look like if gs8
8:02
588 proves to be effective and safe in
8:05
this Phase 1 billion trial the drug will
8:07
move on to larger Phase 2 and phase
8:09
three trials where it will be tested in
8:11
more people and in different
8:13
settings this is a slow process but it's
8:16
how every medical breakthrough happens
8:18
remember it wasn't that long ago that
8:20
art was considered groundbreaking and
8:22
now it's a standard life-saving
8:25
treatment if all goes well we could be
8:27
looking at a new addition to the HIV
8:29
treatment toolbox one that brings us
8:31
closer to long-term viral suppression or
8:33
even a functional cure the key takeaway
8:37
progress each new study including gs8
8:40
588 is a step forward in our
8:43
understanding of HIV and how we might
8:47
virus that's it for today's Deep dive
8:49
into the GS 8588 study if you found this
8:53
video informative and want to stay
8:54
updated on the latest in HIV research
8:57
and other health topics don't forget to
8:58
hit that subscribe button and turn on
9:01
notifications let me know your thoughts
9:03
on this trial in the comments below what
9:06
are your hopes for the future of HIV
9:08
treatment I'd love to hear from you
9:10
thanks for watching stay safe and I'll
9:12
see you in the next video
